POLE and neoplasm: It should also be noted that as a single biomarker survey of POLE hotspot exons in ECs of predominantly endometrioid histology, we are presently unable to determine the effect of the about 10% of pathogenic variants outside exons 9 and 13, (11,12) or whether the effect of POLE mutation varies according to tumor molecular subtypes.